Health | Wealth | Happiness

Date: 07th August, 2026

To,	To,
Manager - Listing Compliance **National Stock Exchange of India Limited** 'Exchange Plaza'. C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 SYMBOL: JSLL	Head of the Department, Department of Listing Operation, **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400001 SCRIP Code: 544476

Subject: Outcome of the Meeting of the Board of Directors of Jeena Sikho Lifecare Limited held on August 07, 2026

Ref: Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform you that the Board of Directors of **Jeena Sikho Lifecare Limited ("the Company"),** at its meeting held today i.e. **Friday, 07th August, 2026** at the registered office situated in SCO 11 First Floor, Kalgidhar Enclave, Mohali, Zirakpur, Punjab, India, 140604 has inter alia, passed the resolutions as set out below:

1. **Approval of Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026 along with Limited Review Report.**

   The Board of Directors, on the recommendation of the Audit Committee, considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026, together with the Limited Review Reports issued by the Statutory Auditors thereon, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The said Financial Results along with the Limited Review Reports are enclosed herewith as **Annexure-I.**

2. **Re-appointment of Mr. Karan Vir Bindra (DIN: 09283623) as an Independent Director of the Company, subject to approval of the shareholders.**

   The Board of Directors, based on the recommendation of Nomination and Remuneration Committee and after due consideration, approved the re-appointment of **Mr. Karan Vir Bindra (DIN: 09283623)** as an **Independent Non-Executive Director** of the Company for a second term of five consecutive years with effect from **25th August 2026 to 24th August 2031,** not liable to retire by rotation, subject to approval of members at the ensuing AGM.

   The Board is of the opinion that Mr. Karan Vir Bindra fulfils the conditions specified under the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for his re-appointment as an Independent Director of the Company and that he is independent of the management.

Registered Office Address:
SCO-11, Kalgidhar Enclave, Baltana, Zirakpur,
Punjab-140604, 01762-513185
CIN NO.: L52601PB2017PLC046545

Corporate Office Address:
B-26, Opp. Metro Pillar No. 223, Rohtak Road,
New Multan Nagar, Delhi - 110056
Email ID.: cs@jeenasikho.com | www.jeenasikho.com

Further, as per the requirement of the Circular No. LIST/COMP/14/2018-19 and SE/CML/2018/24 dated June 20, 2018 issued by the BSE and NSE respectively, we hereby confirm that Mr. Karan Vir Bindra is not debarred from holding the office of Director by virtue of any Order passed by the Securities and Exchange Board of India or any other such authority.

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026 is enclosed as **Annexure-II.**

3. **Re-appointment of Mrs. Bhavna Grover (DIN: 07557913) as a Whole-time Director of the Company, subject to approval of the shareholders.**

The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee and after due consideration, approved reappointment of **Mrs. Bhavna Grover (DIN: 07557913)** as **Whole-Time Director and Key Managerial Personnel** of the Company, liable to retire by rotation, for a period of five consecutive years with effect from **25th August 2026 to 24th August 2031**, subject to approval of members at the ensuing AGM.

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026 is enclosed as **Annexure-III.**

4. **Re-Appointment of Mr. Manish Grover (DIN: 07557886), as Managing Director of the Company, subject to approval of the shareholders.**

The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee and after due consideration, approved reappointment of **Mr. Manish Grover (DIN: 07557886) as Managing Director and Key Managerial Personnel** of the Company, liable to retire by rotation, for a period of five consecutive years with effect from **25th August 2026 to 24th August 2031**, subject to approval of members at the ensuing AGM.

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026 is enclosed as **Annexure-IV.**

Registered Office Address:
SCO-11, Kalgidhar Enclave, Baltana, Zirakpur, Punjab-140604, 01762-513185
CIN NO.: L52601PB2017PLC046545

Corporate Office Address:
B-26, Opp. Metro Pillar No. 223, Rohtak Road, New Multan Nagar, Delhi - 110056
Email ID.: cs@jeenasikho.com | www.jeenasikho.com

The meeting of the Board of Directors of the Company commenced at 4:30 p.m. IST and concluded at 04:42 p.m. IST

The above intimation is also being made available on the Company's website at www.jeenasikho.com

You are requested to take the above information on record and disseminate the same on your website.

Thanking you,

Yours faithfully,
For Jeena Sikho Lifecare Limited

MANISH GROVER
Digitally signed by MANISH GROVER
Date: 2026.08.07 19:14:03 +05'30'

Manish Grover
Managing Director
DIN: 07557886

Date: 07.08.2026
Place: Zirakpur, Punjab

Registered Office Address:
SCO-11, Kalgidhar Enclave, Baltana, Zirakpur, Punjab-140604, 01762-513185
CIN NO.: L52601PB2017PLC046545

Corporate Office Address:
B-26, Opp. Metro Pillar No. 223, Rohtak Road, New Multan Nagar, Delhi - 110056
Email ID.: cs@jeenasikho.com | www.jeenasikho.com

Walker Chandiok & Co LLP

B-309, 3rd Floor,
Elante Office Building,
Industrial Area, Phase I,
Chandigarh - 160 002
India

T +91 172 403 8182

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jeena Sikho Lifecare Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Jeena Sikho Lifecare Limited ('the Company') for the quarter ended 30 June 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The review of standalone unaudited quarterly financial results for the period ended 30 June 2025, included in the Statement was carried out and reported by KRA and Co. Chartered Accountants who has expressed unmodified conclusion vide their review report dated 14 August 2025, whose review report has been furnished to us and which has been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Sandeep Mehta

Digitally signed by Sandeep Mehta
Date: 2026.08.07 19:16:04 +05'30'

Sandeep Mehta
Partner
Membership No.: 099410
UDIN: 26099410MYHGLT3248

Place: Chandigarh
Date: 07 August 2026

Walker Chandiok & Co LLP

B-309, 3rd Floor,
Elante Office Building,
Industrial Area, Phase I,
Chandigarh - 160 002
India

T +91 172 403 8182

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jeena Sikho Lifecare Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Jeena Sikho Lifecare Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 30 June 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review report of other auditor referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We did not review the interim financial results of one subsidiary included in the Statement, whose financial information reflects total revenues of ₹ Nil, total net loss after tax of ₹ 11.68 lacs and total comprehensive loss of ₹ 11.27 lacs, for the quarter ended on 30 June 2026, as considered in the Statement. These interim financial results have been reviewed by other auditor whose review report has been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the report of the other auditor.

6. The Statement includes the interim financial results of one subsidiary, which have not been reviewed by their auditor, whose interim financial results reflects total revenues of ₹ Nil, net profit after tax of ₹ 31.11 lacs and total comprehensive income of ₹ 31.10 lacs for the quarter ended 30 June 2026 as considered in the Statement, and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, are based solely on such unreviewed interim financial results. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

   Our conclusion is not modified in respect of this matter with respect to our reliance on the financial results certified by the Board of Directors.

7. The review of unaudited consolidated quarterly financial results for the period ended 30 June 2025, included in the Statement was carried out and reported by KRA & Co. Chartered Accountants who have expressed unmodified conclusion vide their review report dated 14 August 2025, whose review report has been furnished to us by the management and which has been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Sandeep Mehta

Digitally signed by Sandeep Mehta
Date: 2026.08.07 19:16:30 +05'30'

Sandeep Mehta
Partner
Membership No.: 099410
UDIN: 26099410UAMMEQ6308

Place: Chandigarh
Date: 07 August 2026

Annexure 1

List of entities included in the Statement

Subsidiaries:

1. Jeena Sikho International LLC
2. Jeena Green Resources Private Limited

JEENA SIKHO LIFECARE LIMITED

Regd. Office : SCO 11, First Floor, Kalgidhar Enclave, Zirakpur, Mohali, Punjab 140604
CIN: L52601PB2017PLC046545

Website: www.jeenasikho.com Email: cs@jeenasikho.com Tel: 91 - 01762-513185

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

(Amount in Rs. lacs)

S. No.	Particulars	Quarter ended			Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		(Unaudited)	Refer note 5	(Unaudited) Refer note 6	(Audited)
1	**Income**				
	a. Revenue from operations	22,440.48	21,555.07	17,428.59	80,134.64
	b. Other income	1,401.51	357.87	106.85	865.89
	Total Income	**23,841.99**	**21,912.94**	**17,535.44**	**81,000.53**
2	**Expenses**				
	a. Purchase of stock-in-trade and ayurvedic healthcare consumables	2,703.05	2,766.30	2,087.47	10,011.39
	b. Changes in inventories of stock-in-trade and ayurvedic healthcare consumables	(136.20)	(275.13)	(254.00)	(862.53)
	c. Employee benefits expense	4,417.79	4,598.60	2,996.15	14,840.48
	d. Finance costs	347.19	372.86	165.98	1,283.35
	e. Depreciation and amortization expense	1,532.78	1,632.35	964.91	4,757.82
	f. Other expenses	6,243.81	6,667.64	4,719.90	21,182.55
	Total Expenses	**15,108.42**	**15,762.62**	**10,680.41**	**51,213.06**
3	**Profit before tax (1-2)**	**8,733.57**	**6,150.32**	**6,855.03**	**29,787.47**
4	**Tax expense / (credit)**				
	a. Current tax	2,137.61	1,788.36	1,778.13	8,017.00
	b. Taxation for earlier years	-	14.10	-	14.10
	c. Deferred tax	26.78	(187.32)	(54.24)	(461.20)
	Total tax expense	**2,164.39**	**1,615.14**	**1,723.89**	**7,569.90**
5	**Profit for the quarter/ year (3-4)**	**6,569.18**	**4,535.18**	**5,131.14**	**22,217.57**
6	**Other comprehensive income**				
	(i) Items that will not be reclassified to profit or loss				
	- Remeasurement gain on defined benefit plans	63.08	6.93	59.02	79.01
	- Income tax related to items that will not be reclassified to profit or loss	(15.87)	(1.74)	(14.85)	(19.88)
7	**Total comprehensive income for the quarter/ year (5+6)**	**6,616.39**	**4,540.37**	**5,175.31**	**22,276.70**
8	**Paid-up equity share capital (Face value of Rs. 2 each)**	2,486.01	2,486.01	2,486.01	2,486.01
9	**Other equity**				44,254.04
10	**Earnings per share (Face value of Rs. 2 each)**				
	Basic (in Rs. not annualised except for year ended 31 March 2026)	5.28	3.65	4.13	17.87
	Diluted (in Rs. not annualised except for year ended 31 March 2026)	5.28	3.64	4.12	17.85
	See accompanying notes to the unaudited financial results				

This space has been intentionally left blank

JEENA SIKHO LIFECARE LIMITED

Regd. Office : SCO 11, First Floor, Kalgidhar Enclave, Zirakpur, Mohali, Punjab 140604
CIN: L52601PB2017PLC046545

Website: www.jeenasikho.com   Email: cs@jeenasikho.com   Tel: 91 - 01762-513185

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

(Amount in Rs. lacs)

S. No.	Particulars	Quarter ended			Year ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		(Unaudited)	Refer note 5	(Unaudited) Refer note 6	(Audited)
1	**Income**				
	a. Revenue from operations	22,440.48	21,555.32	17,428.59	80,136.39
	b. Other income	1,432.65	341.59	106.85	849.61
	Total Income	**23,873.13**	**21,896.91**	**17,535.44**	**80,986.00**
2	**Expenses**				
	a. Purchase of stock-in-trade and ayurvedic healthcare consumables	2,704.71	2,768.59	2,088.71	10,020.21
	b. Changes in inventories of stock-in-trade and ayurvedic healthcare consumables	(137.86)	(277.73)	(255.24)	(867.23)
	c. Employee benefits expense	4,417.79	4,598.60	2,996.15	14,840.48
	d. Finance costs	347.35	372.70	165.98	1,283.35
	e. Depreciation and amortisation expense	1,538.89	1,638.39	965.16	4,769.20
	f. Other expenses	6,249.26	6,673.75	4,723.70	21,200.64
	Total Expenses	**15,120.14**	**15,774.30**	**10,684.46**	**51,246.65**
3	**Profit before tax (1-2)**	**8,752.99**	**6,122.61**	**6,850.98**	**29,739.35**
4	**Tax expense / (credit)**				
	a. Current tax	2,137.61	1,788.36	1,778.13	8,017.00
	b. Taxation for earlier years	-	14.10	-	14.10
	c. Deferred tax	26.37	(187.62)	(54.29)	(461.56)
	Total tax expense	**2,163.98**	**1,614.84**	**1,723.84**	**7,569.54**
5	**Profit for the quarter/ year (3-4)**	**6,589.01**	**4,507.77**	**5,127.14**	**22,169.81**
6	**Other comprehensive income**				
	(i) Items that will not be reclassified to profit or loss				
	- Remeasurement gain on defined benefit plans	63.09	6.93	59.02	79.01
	- Income tax related to items that will not be reclassified to profit or loss	(15.87)	(1.74)	(14.85)	(19.88)
	(ii) Item that may be reclassified to profit or loss				
	- Exchange differences on translation of foreign operations	-	0.32	-	0.32
7	**Total comprehensive income for the quarter/ year (5+6)**	**6,636.23**	**4,513.28**	**5,171.31**	**22,229.26**
	Profit for the period attributable to:				
	Owners of the parent	6,594.54	4,513.13	5,129.10	22,185.08
	Non-controlling interests	(5.53)	(5.36)	(1.96)	(15.27)
	Other comprehensive income for the period attributable to:				
	Owners of the parent	47.22	5.51	44.17	59.45
	Non-controlling interests	-	-	-	-
	Total comprehensive income for the period attributable to:				
	Owners of the parent	6,641.76	4,518.64	5,173.27	22,244.53
	Non-controlling interests	(5.53)	(5.36)	(1.96)	(15.27)
8	**Paid-up equity share capital (Face value of Rs. 2 each)**	**2,486.01**	**2,486.01**	**2,486.01**	**2,486.01**
9	**Other equity**				44,221.87
10	**Earnings per share (Face value of Rs. 2 each)**				
	Basic (in Rs. not annualised except for year ended 31 March 2026)	5.30	3.63	4.12	17.84
	Diluted (in Rs. not annualised except for year ended 31 March 2026)	5.29	3.62	4.12	17.81
	See accompanying notes to the unaudited financial results				

This page has been intentionally left blank

JEENA SIKHO LIFECARE LIMITED

Regd. Office : SCO 11, First Floor, Kalgidhar Enclave, Zirakpur, Mohali, Punjab 140604
CIN: L52601PB2017PLC046545

Website: www.jeenasikho.com Email: cs@jeenasikho.com Tel: 91 - 01762-513185

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

Segment-wise revenue and results for the quarter ended 30 June 2026

(Amount in Rs. lacs)

Particulars	Quarter ended (Refer note 4)			Year ended (Refer note 4)
	30.06.2026	**31.03.2026**	**30.06.2025**	**31.03.2026**
	(Unaudited)	Refer note 5	(Unaudited) Refer note 6	(Audited)
Segment Revenue				
Ayurvedic products/ medicines	11,828.31	11,797.98	8,002.51	41,569.28
Ayurvedic healthcare services	10,474.66	9,532.10	9,426.08	38,340.37
Others	137.51	225.24	-	226.74
Subtotal	**22,440.48**	**21,555.32**	**17,428.59**	**80,136.39**
Revenue from operations	**22,440.48**	**21,555.32**	**17,428.59**	**80,136.39**
Segment Results				
Ayurvedic products/ medicines	4,124.11	3,946.21	3,010.81	16,457.42
Ayurvedic healthcare services	4,271.13	2,829.53	4,287.48	15,636.07
Others	137.51	247.15	-	226.74
Subtotal	**8,532.75**	**7,022.89**	**7,298.29**	**32,320.23**
Unallocabled expenses/ income:				
Less- Finance cost	(347.35)	(372.86)	(165.98)	(1,283.35)
Add- Other unallocable income	1,401.51	341.59	106.85	849.61
Less- Other unallocable expenses *	(833.92)	(869.01)	(388.18)	(2,147.14)
Profit before tax	**8,752.99**	**6,122.61**	**6,850.98**	**29,739.35**

*** For internal reporting purposes, the Company's CODM allocates unallocable expenses as presented above in the proportion of respective segment revenue.**

This page has been intentionally left blank

Notes to standalone and consolidated financial results:

1 The statutory auditors have reviewed the standalone and consolidated financial results of Jeena Sikho Lifecare Limited (“the Holding Company”) and its subsidiaries namely Jeena Green Resources Private Limited and Jeena Sikho International LLC (together referred to as “the Group”) for the quarter ended 30 June 2026. In terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, these standalone and consolidated financial results (“financial results”) for the quarter ended 30 June 2026 were reviewed by the Audit Committee at its meeting held on 07 August 2026 and approved by the Board of Directors at their meeting held on 07 August 2026.

2 The above standalone and consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

3 The financial results of the subsidiary Jeena Sikho International LLC incorporated on 11 September 2025, for the current quarter ending 30 June 2026 have not been reviewed by the statutory auditor and are management certified. However, the management has exercised necessary due diligence to ensure that the unaudited standalone financial results for the aforementioned quarter provide a fair view of the Company's affairs.

4 As per Ind AS 108 operating segment is a component of the Group that engages in business activities whose operating results are regularly reviewed by the Group's Chief Operating Decision Maker ('CODM)' to make decisions about resources to be allocated to the segment and assess its performance; and for which discrete financial information is available. Accordingly, The Group has identified the following operating segments:
a) Ayurvedic Products and Medicines
b) Ayurvedic Healthcare Services
c) Others- significantly comprising royalty income, revenue share of income from diagnostic services,

The CODM does not review assets and liabilities for each operating segment separately, hence segment information relating to the total assets and liabilities has not been furnished.

In accordance with Ind AS 108 "Operating Segments", the Company has opted to present segment information along with the consolidated financial results of the Group.

5 The figures for the quarter ended 31 March 2026 are the balancing figures between the audited standalone and consolidated figures for the full financial year ending 31 March 2026 and the published figures up to nine months of the respective financial year. The figures up to nine months ended 31 December 2025 were subjected to limited review by the statutory auditor.

6 The comparative standalone and consolidated financial information of the Company for the quarter ended 30 June 2025 were audited by the KRA & Co, Chartered Accountants, the predecessor auditor, who have expressed an unmodified opinion.

7 On 19 June 2026, the Board of Directors of Jeena Sikho Lifecare Limited approved the sale of the land and building comprising its Derabassi hospital facility to M/s VSB Enterprises for a total consideration of ₹9.05 crore. The transaction is expected to be completed during the quarter ending 30 September 2026. The Derabassi hospital contributes approximately 6% to 8% of the Company's total revenue. Following the sale, the Company intends to continue operating the hospital from the same premises under a proposed lease arrangement. Accordingly, the transaction is not expected to have any material adverse impact on the Company's business operations or revenue-generating activities.

8 During the year ending 31 March 2026, Jeena Sikho Lifecare Limited (“the Company”) extended financial assistance to its wholly owned subsidiary, Jeena Sikho International LLC (“JSIL”), for its international operations.

JSIL had entered into a Share Purchase Agreement dated 07 January 2026 to acquire a 51% equity stake in Back to Roots Ayurveda by Dr. Shyam LLC (“BTRS”), UAE. The arrangement involved funding of AED 15.3 lacs (approximately Rs. 394.27 lacs) to existing shareholders and AED 60 lacs (approximately Rs. 1,546.16 lacs) to the Company, of which AED 15.3 lacs (approximately Rs. 394.27 lacs) to shareholders and AED 21.10 lacs (approximately Rs. 543.73 lacs) to the Company which were disbursed during the quarter and year ended 31 March 2026.

As at 30 June 2026, the share transfer is pending completion of regulatory formalities, including commercial registration with the Department of Economic Development (DED), Abu Dhabi and amendment of the Memorandum of Association (MoA). Accordingly, the amount paid is classified as advance for investment in consolidated financial results. Further, as per the agreement, the profit share Rs. 0.53 Crores has been booked in the consolidated financial results of the quarter ending 30 June 2026.

9 During the current quarter, the Board of Directors of the Company at its meeting held on 30 May 2026, recommended final dividend of Rs. 4.50 per equity share to the shareholders of Jeena Sikho Lifecare Limited for the year ended 31 March 2026, subject to the approval of shareholders of the Company in the forthcoming Annual General Meeting.

Place: Zirakpur, Punjab
Date: 07 August 2026

For Jeena Sikho Lifecare Limited

MANISH GROVER Digitally signed by MANISH GROVER Date: 2026.08.07 19:14:28 +05'30'

Manish Grover
Managing Director
DIN - 07557886

Annexure II

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026:

<u>Reappointment of Mr. Karan Vir Bindra</u>

Sr. No	**Details of events that need to be provided**	**Details of Change**
1	Reason for change viz. appointment, ~~resignation, removal, death or otherwise;~~	The Members of the Company, at the Extra Ordinary General Meeting held on 25th August, 2021 approved the appointment of Mr. Karan Vir Bindra (DIN: 09283623) as an Independent Director of the Company, not liable to retire by rotation, for a first term of five (5) consecutive years commencing from August 25, 2021 up to August 24, 2026 (both days inclusive). Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors considered and recommended the re-appointment of Mr. Karan Vir Bindra (DIN: 09283623), as an Independent Non-Executive Director of the Company, not liable to retire by rotation, for a second term of five consecutive years with effect from **25th August 2026 to 24th August 2031**, to the members by way of a special resolution at the ensuing AGM of the Company.
2	Date of Re-appointment and term of Re-appointment	Date of Re-appointment: with effect from 25th August 2026. Term of Re-appointment: For a second term of five consecutive years with effect from 25th August 2026 to 24th August 2031.
3	Brief profile (in case of appointment)	**Mr. Karan Vir Bindra (DIN: 09283623)** is a Non-Executive Independent Director of Jeena Sikho Lifecare Limited. He is a Fellow Member of the Institute of Company Secretaries of India (FCS) and holds a Bachelor's degree in Law (LL.B.) and a Bachelor's degree in Commerce. He brings more than 12 years of professional experience in corporate laws, secretarial compliance, corporate governance, regulatory advisory, and compliance management. He is a practicing Company Secretary and the proprietor of M/s K. V. Bindra & Associates, providing advisory services in areas relating to corporate compliance, securities laws, governance matters,

Registered Office Address:
SCO-11, Kalgidhar Enclave, Baltana, Zirakpur, Punjab-140604, 01762-513185
CIN NO.: L52601PB2017PLC046545

Corporate Office Address:
B-26, Opp. Metro Pillar No. 223, Rohtak Road, New Multan Nagar, Delhi - 110056
Email ID.: cs@jeenasikho.com | www.jeenasikho.com

		FEMA, and regulatory requirements. Over the years, Mr. Bindra has advised various listed and unlisted companies on matters relating to statutory compliances, corporate governance frameworks, regulatory filings, and corporate law matters. His extensive knowledge and experience in governance and regulatory affairs enable him to provide valuable guidance to the Board in strengthening compliance practices, enhancing governance standards, and ensuring adherence to applicable statutory requirements.
4	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable
5	Information as required pursuant to BSE circular no. LIST/COMP/14/2018-19 and NSE circular no. NSE/CML/2018/24, dated June 20, 2018	**Mr. Karan Vir Bindra** is not debarred from holding office of Directors by virtue of any order passed by Securities and Exchange Board of India or any other authority

Registered Office Address:
SCO-11, Kalgidhar Enclave, Baltana, Zirakpur,
Punjab-140604, 01762-513185
CIN NO.: L52601PB2017PLC046545

Corporate Office Address:
B-26, Opp. Metro Pillar No. 223, Rohtak Road,
New Multan Nagar, Delhi - 110056
Email ID.: cs@jeenasikho.com | www.jeenasikho.com

Annexure III

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026:

Reappointment of Mrs. Bhavna Grover

Sr. No	Details of events that need to be provided	Details of Change
1	Reason for change viz. appointment, ~~resignation, removal, death or otherwise;~~	The Members of the Company had, at the Extra Ordinary General Meeting held on 25th August, 2021, approved the appointment of Mrs. Bhavna Grover (DIN: 07557913) as Whole-time Director of the Company for a period of five (5) consecutive years commencing from **25 August 2021** and ending on **24 August 2026**. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors considered and recommended the re-appointment of Mrs. Bhavna Grover (DIN: 07557913), as Whole Time Director and key Managerial Personnel of the Company, liable to retire by rotation, for another term of five consecutive years with effect from **25th August 2026 to 24th August 2031**, to the members by way of a special resolution at the ensuing AGM of the Company.
2	Date of Re-appointment and term of Re-appointment	Date of Re-appointment: with effect from 25th August 2026. Term of Re-appointment: For another term of five consecutive years with effect from 25th August 2026 to 24th August 2031.
3	Brief profile (in case of appointment)	Mrs. Bhavna Grover is the Whole-Time Director of the Company and has been associated with the Board of Jeena Sikho Lifecare Limited since its incorporation. She brings experience in human resource management, legal administration, finance, and organizational processes. Over the years, she has played an important role in managing and strengthening the Company's internal systems, financial planning processes, administrative frameworks, and operational controls.

		Her focus on process improvement, compliance, and effective resource management has contributed to the Company's operational stability, governance practices, and sustainable growth.
4	Disclosure of relationships between directors (in case of appointment of a director)	Mrs. Bhavna Grover is the spouse of Mr. Manish Grover, Managing Director of the Company, and the mother of Ms. Shreya Grover, Whole-time Director of the Company. Mr. Manish Grover and Mrs. Bhavna Grover have been serving on the Board since the incorporation of the Company and are Promoters of the Company.
5	Information as required pursuant to BSE circular no. LIST/COMP/14/2018-19 and NSE circular no. NSE/CML/2018/24, dated June 20, 2018	**Mrs. Bhavna Grover** is not debarred from holding office of Directors by virtue of any order passed by Securities and Exchange Board of India or any other authority

Registered Office Address:
SCO-11, Kalgidhar Enclave, Baltana, Zirakpur,
Punjab-140604, 01762-513185
CIN NO.: L52601PB2017PLC046545

Corporate Office Address:
B-26, Opp. Metro Pillar No. 223, Rohtak Road,
New Multan Nagar, Delhi - 110056
Email ID.: cs@jeenasikho.com | www.jeenasikho.com

<u>**Annexure IV**</u>

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026:

<u>**Reappointment of Mr. Manish Grover**</u>

Sr. No	Details of events that need to be provided	Details of Change
1	Reason for change viz. appointment, ~~resignation, removal, death or otherwise;~~	The Members of the Company had, at the Extra Ordinary General Meeting held on 25th August, 2021, approved the appointment of Mr. Manish Grover (DIN: 07557886) as a Managing Director of the Company for a period of five (5) consecutive years commencing from **25 August 2021** and ending on **24 August 2026**. Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors considered and recommended the re-appointment of Mr. Manish Grover (DIN: 07557886), as Managing Director and key Managerial Personnel of the Company, liable to retire by rotation, for another term of five consecutive years with effect from **25th August 2026 to 24th August 2031**, to the members by way of a special resolution at the ensuing AGM of the Company.
2	Date of Re-appointment and term of Re-appointment	Date of Re-appointment: with effect from 25th August 2026. Term of Re-appointment: For another term of five consecutive years with effect from 25th August 2026 to 24th August 2031
3	Brief profile (in case of appointment)	Mr. Manish Grover is the Managing Director of Jeena Sikho Lifecare Limited and the founder of Shuddhi Ayurveda. He is an entrepreneur and healthcare professional having experience in the Ayurvedic healthcare sector. He has dedicated his professional journey to the revival and promotion of traditional Ayurvedic wisdom and preventive healthcare practices in India. With a focused mission to address the root causes of chronic and lifestyle-related diseases through natural and integrative therapies.

Registered Office Address:
SCO-11, Kalgidhar Enclave, Baltana, Zirakpur, Punjab-140604, 01762-513185
CIN NO.: L52601PB2017PLC046545

Corporate Office Address:
B-26, Opp. Metro Pillar No. 223, Rohtak Road, New Multan Nagar, Delhi - 110056
Email ID.: cs@jeenasikho.com | www.jeenasikho.com

		Since commencing his professional journey in 2009, Mr. Grover has been actively involved in promoting Ayurveda, preventive healthcare, and holistic wellness practices. He has played a significant role in establishing and expanding the Company's healthcare ecosystem, including the growth of Shuddhi Ayurveda and HIIMS (Hospital & Institute of Integrated Medical Sciences), with a focus on integrating Ayurveda, lifestyle management, yoga, and wellness practices. Under his leadership, the Company has expanded its presence in the Ayurvedic healthcare segment and developed a structured healthcare ecosystem supported by a team of healthcare professionals, including doctors and researchers, engaged in advancing Ayurvedic treatment approaches through clinical experience and research-based practices. His areas of expertise include Ayurvedic healthcare, preventive wellness, lifestyle management, healthcare operations, business strategy, and organizational leadership. He continues to contribute towards strengthening the Company's vision of providing holistic and integrative healthcare solutions.
4	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Manish Grover is the spouse of Mrs. Bhavna Grover, Whole-time Director of the Company, and the father of Ms. Shreya Grover, Whole-time Director of the Company. Mr. Manish Grover and Mrs. Bhavna Grover have been serving on the Board since the incorporation of the Company and are Promoters of the Company.
5	Information as required pursuant to BSE circular no. LIST/COMP/14/2018-19 and NSE circular no. NSE/CML/2018/24, dated June 20, 2018	**Mr. Manish Grover** is not debarred from holding office of Directors by virtue of any order passed by Securities and Exchange Board of India or any other authority

Registered Office Address:
SCO-11, Kalgidhar Enclave, Baltana, Zirakpur,
Punjab-140604, 01762-513185
CIN NO.: L52601PB2017PLC046545

Corporate Office Address:
B-26, Opp. Metro Pillar No. 223, Rohtak Road,
New Multan Nagar, Delhi - 110056
Email ID.: cs@jeenasikho.com | www.jeenasikho.com